Dermata Therapeutics Inc Stock Price, News & Analysis

Dermata Therapeutics announced positive efficacy and safety results from its Phase 1b proof of concept study evaluating DMT410, a topical treatment for aesthetic skin conditions. Key findings include observed improvements in pore size, luminosity, and overall skin brightness, lasting approximately 3 months. The study, involving 10 female patients, showed no adverse effects or distant spread of toxin. The company believes DMT410's delivery method expands market opportunities for botulinum toxins. Results were presented at The American Society for Dermatologic Surgery Annual Meeting.

Dermata Therapeutics (Nasdaq:DRMA) has enrolled its first patient in a Phase 2 trial for DMT310, aimed at treating moderate-to-severe rosacea, which affects approximately 16 million patients in the U.S. This trial, designed to evaluate the product's tolerability and efficacy over 12 weeks, anticipates topline results in the second half of 2022. DMT310 employs innovative Spongilla technology, targeting inflammatory pathways by inhibiting IL-17 production. If successful, it could redefine treatment options in dermatology, potentially becoming the first once-weekly topical solution for rosacea.

Dermata Therapeutics reported positive topline results from its DMT310 clinical trial for mild-to-moderate psoriasis, with 29.6% of patients achieving a PGA score of 0 or 1. The company successfully closed an upsized initial public offering (IPO) raising $18.0 million and appointed notable leaders to its Board and executive team. Dermata plans to present topline results from the DMT410 study on November 19, 2021, and initiate a Phase 2 study for DMT310 in rosacea in Q4 2021. As of September 30, 2021, Dermata had $12.6 million in cash, bolstered by its recent IPO.

Dermata Therapeutics (Nasdaq:DRMA) announced the presentation of efficacy and safety results for its Phase 1b proof of concept study evaluating DMT410 for treating multiple aesthetic skin conditions. The study, involving 10 patients, observed effects over 16 weeks and assessed various endpoints, including fine lines and luminosity improvements. Results will be presented by Dr. Rawaa Almukhtar at the ASDS Annual Meeting on November 19, 2021. DMT410 utilizes unique Spongilla technology for intradermal delivery of botulinum toxin.

Dermata Therapeutics (NASDAQ:DRMA) will host a virtual investor event on November 19, 2021, at 4:30 PM ET to present results of its DMT410 Phase 1b study targeting multiple aesthetic skin conditions. The event features presentations from Dr. Christopher Nardo and Gerry Proehl, focusing on the proof of concept evaluation initially shared at the American Society for Dermatologic Surgery meeting. DMT410 utilizes Dermata's Spongilla technology to deliver botulinum toxin topically and may offer a new treatment avenue for skin conditions.

Dermata Therapeutics (NASDAQ:DRMA) announced positive results from its Phase 1b trial of DMT310 for treating mild-to-moderate psoriasis. The study showed that 29.6% of patients achieved a Physician's Global Assessment (PGA) score of 0 or 1, while 25.9% had a Psoriasis Area Severity Index (PASI) score of 0 or 1 after 8 weeks. Additionally, there was a 19.6% reduction in pruritus. The treatment was reported to be safe with few adverse events. Dermata plans to advance DMT310 in further clinical investigations.

Dermata Therapeutics (Nasdaq:DRMA) announced an oversubscribed $18 million IPO, enhancing its clinical development focus. The company aims to release topline data from its DMT310 Phase 1b study for psoriasis in 4Q 2021 and initiate a Phase 2 study for rosacea later this year. Financial results reveal cash reserves of $427,202 as of June 30, 2021, down from $530,400 at year-end 2020. R&D expenses rose significantly to $867,197 for Q2 2021 from $411,949 in Q2 2020, reflecting increased clinical trial costs. General expenses also increased sharply, highlighting rising operational costs.

Dermata Therapeutics (NASDAQ:DRMA)(NASDAQ:DRMAW) will present efficacy and safety data from a Phase 1b study evaluating DMT410 as a new topical delivery mechanism for botulinum toxin aimed at aesthetic skin conditions at the ASDS 2021 Annual Meeting on November 19-21, 2021. The study involved 10 patients receiving DMT410, comprising a topical application of Spongilla powder followed by botulinum toxin, with observed outcomes over 16 weeks. The presentation signifies Dermata's commitment to innovative treatments in dermatology.

Dermata Therapeutics (NASDAQ:DRMA, DRMAW) announced the appointment of Kyri Van Hoose as Senior Vice President and Chief Financial Officer, succeeding Thomas Insley, who will retire but remain as a financial consultant. With over 20 years of finance experience in the life sciences, Ms. Van Hoose aims to drive Dermata's growth and support development programs for DMT310 and DMT410. CEO Gerry Proehl expressed confidence in her ability to enhance corporate value and navigate the company’s future as a public entity.